Skip to main content
Clinical Trials/NCT00603083
NCT00603083
Completed
Phase 4

Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia

Vejle Hospital2 sites in 1 country60 target enrollmentJanuary 2008

Overview

Phase
Phase 4
Intervention
Ropivacaine, Ketorolac and Adrenalin
Conditions
Pain, Postoperative
Sponsor
Vejle Hospital
Enrollment
60
Locations
2
Primary Endpoint
Pain score
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the investigator standardized pain treatment plus local pain treatment is more effective than the investigator standardized pain treatment plus placebo in total hip arthroplasty.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
October 2008
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Per Kjaersgaard-Andersen

Per Kjaersgaard-Andersen MD

Vejle Hospital

Eligibility Criteria

Inclusion Criteria

  • Scheduled for an uncemented unilateral Total Hip Replacement because of osteoarthritis
  • Willingness and possibility to follow the instructions of the study
  • 18 years or older
  • written informed consent and authority after it has been read and understood.

Exclusion Criteria

  • Operation with anterior approach or using navigation
  • Do not understand or speech danish
  • Can not use the pain-score Numerical Rating Scale (NRS)
  • Special indications for Total Hip Replacement
  • Anaesthetized in general anaesthesia where a tube is demanded
  • Daily use of strong opioids, based on the investigators assessment
  • Fertile women
  • ASA-score: 3 and 4
  • Known allergy against the standardized pain treatment, the study drugs and placebo, Ropivacaine, Ketorolac, Adrenalin.
  • Treatment with Lithium, Dihydroergotamin, full anticoagulant treatment or MAO-inhibitor

Arms & Interventions

A

This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.

Intervention: Ropivacaine, Ketorolac and Adrenalin

B

This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.

Intervention: Placebo

Outcomes

Primary Outcomes

Pain score

Time Frame: 24 hours

Opioid Consumption

Time Frame: 24 hours

Secondary Outcomes

  • Pain score(7 days)
  • Opioid consumption(3 days)
  • Postoperative Nausea and Vomiting (PONV)(3 days)
  • Fatigue(3 days)
  • Physical function(2 month)

Study Sites (2)

Loading locations...

Similar Trials